FY26 delivery order
Ended Awarded Last action
- Contract number
- 36C26326N0166
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 23
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $226,496
Award facts
- Contract value 100% obligated
- $226,496.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Iowa City, IA 52246, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$452,993 | |
| Original award | $679,489 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a Fiscal Year 2026 delivery order valued at $226,496.40 by Veterans Integrated Service Network 23 (VA) on October 1, 2025, with an ultimate completion date of September 30, 2026. This firm fixed-price delivery order carries no set-aside designation and is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract. The work will be performed in Iowa City, Iowa, and involves the supply of radiopharmaceutical products, principally PYLARIFY (piflufolastat F-18), a diagnostic imaging agent used in positron emission tomography scans for prostate cancer detection and localization in federal healthcare settings serving veterans.
This delivery order represents a continuation of Progenics' substantial federal contracting relationship with the VA system, through which the company has received over 150 individual contract awards across multiple Veterans Integrated Service Networks. The award is issued against a broader $290 million Federal Supply Schedule contract established in April 2025 with VISN 12 extending through March 2030, which serves as a master vehicle enabling efficient procurement of radiopharmaceutical supplies across the VA healthcare system. Progenics maintains an established federal presence as a critical supplier of specialized nuclear medicine products and diagnostic imaging agents to VA medical centers, the Defense Health Agency, and the National Institutes of Health, with manufacturing and distribution operations based primarily in North Billerica, Massachusetts.
Quick answers
Who was awarded contract 36C26326N0166?
36C26326N0166 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 23 (Veterans Health Administration) on October 1, 2025.
How much is contract 36C26326N0166 worth?
The government has obligated $226,496 on 36C26326N0166.
Is contract 36C26326N0166 an order under another contract?
Yes. 36C26326N0166 is a delivery order under 36F79725D0093, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26326N0166 competed?
The extent of competition for 36C26326N0166 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award